Anixa Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Anixa Biosciences generated cash of -$6,209,000, which is more than the previous year. Cash used in financing activities reached the amount of $366,000 last year. Net change in cash is therefore -$11,445,000.
Cash Flow
| 2014 | -2.37M | -2.50M | 7.34M |
|---|---|---|---|
| 2015 | 1.36M | 45.22K | -400.61K |
| 2016 | -3.38M | 1.50M | -2.67K |
| 2017 | -3.79M | -2.73M | 7.38M |
| 2018 | -4.27M | 1.46M | 2.52M |
| 2019 | -4.74M | -525.45K | 5.70M |
| 2020 | -6.17M | -305.79K | 9.40M |
| 2021 | -4.93M | -3.91M | 31.56M |
| 2022 | -6.49M | -10.72M | 452K |
| 2023 | -6.20M | -5.60M | 366K |
ANIX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 12.36M | 29.12M | 6.41M | 3.49M | 3.05M | 3.33M | 2.48M | 4.36M | 3.36M | 898.17K |
Operating activities | ||||||||||
Net income | -9.93M | -13.77M | -13.12M | -10.09M | -11.81M | -14.24M | -5.00M | -5.01M | -1.37M | -9.60M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 46K | 42K | 59.86K | 90.15K | 466.30K | 343.73K | 368.51K | 358.62K | 325.29K | 314.45K |
Stock-based compensation expense | 4.42M | 6M | 7.50M | 3.92M | 5.71M | 0 | 1.22M | 873.56K | 2.67M | 3.14M |
| Deferred income tax benefit | 4.42M | 6M | 7.50M | 3.92M | 5.71M | 0 | 1.22M | 873.56K | 2.67M | 3.14M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -224K | -29K | 0 | 64.29K | 271.7K | -258.99K | 107.1K | 0 | 400K | -225K |
Inventories | 224K | 29K | 0 | -64.29K | -271.7K | 0 | 0 | 0 | 0 | 452.40K |
Accounts payable | -59K | 129K | -96.17K | -353.44K | 3.80K | 101.68K | 107.1K | 87.99K | -868.66K | -27.04K |
Cash generated by operating activities | -6.20M | -6.49M | -4.93M | -6.17M | -4.74M | -4.27M | -3.79M | -3.38M | 1.36M | -2.37M |
Investing activities | ||||||||||
Purchases Of Investments | -44.41M | -22.48M | -16.49M | -5.01M | -3.85M | -4.25M | -5.50M | -1.9M | -2.9M | -5.2M |
Investments In Property Plant And Equipment | 0 | 0 | 0 | -15.79K | -175.45K | -38.40K | -30.18K | -146.52K | -54.77K | -6.68K |
Acquisitions Net | 0 | 0 | 6.47K | 5.01M | 3.85M | 4.25M | 45K | 1.9M | 2.9M | 0 |
Cash generated by investing activities | -5.60M | -10.72M | -3.91M | -305.79K | -525.45K | 1.46M | -2.73M | 1.50M | 45.22K | -2.50M |
Financing activities | ||||||||||
Common Stock Issued | 92K | 97K | 31.12M | 9.26M | 5.52M | 2.47M | 10.88M | 0 | 0 | 3.67M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | -500K | 0 | -445.25K | 16.4K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -200K |
Cash used in financing activities | 366K | 452K | 31.56M | 9.40M | 5.70M | 2.52M | 7.38M | -2.67K | -400.61K | 7.34M |
Net Change In Cash | -11.44M | -16.76M | 22.71M | 2.92M | 435.73K | -283.48K | 851.05K | -1.88M | 1.00M | 2.46M |
Cash at end of period | 915K | 12.36M | 29.12M | 6.41M | 3.49M | 3.05M | 3.33M | 2.48M | 4.36M | 3.36M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |